Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation

Circulation. 2005 Mar 22;111(11):1448-54. doi: 10.1161/01.CIR.0000158483.13093.9D.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Arteriosclerosis / etiology
  • Arteriosclerosis / physiopathology
  • C-Reactive Protein / analysis
  • Cytokines / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / physiopathology
  • Food / adverse effects
  • Gene Expression Regulation
  • Humans
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / physiopathology
  • Hyperinsulinism / complications
  • Hyperinsulinism / physiopathology
  • Hypertension / complications
  • Hypertension / physiopathology
  • Hypertriglyceridemia / complications
  • Hypertriglyceridemia / physiopathology
  • Hypoglycemic Agents / pharmacology
  • Inflammation / complications
  • Inflammation / genetics
  • Inflammation / physiopathology
  • Insulin / pharmacology
  • Insulin / physiology
  • Insulin Resistance
  • Lipoproteins, HDL / metabolism
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / physiopathology*
  • Models, Biological
  • NF-kappa B / metabolism
  • Obesity / complications
  • Obesity / physiopathology
  • Oxidative Stress
  • Plasminogen Activator Inhibitor 1 / blood
  • Rats

Substances

  • Cytokines
  • Hypoglycemic Agents
  • Insulin
  • Lipoproteins, HDL
  • NF-kappa B
  • Plasminogen Activator Inhibitor 1
  • C-Reactive Protein